Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Cape Fear Valley Medical Center Cancer Center
mi
from
Fayetteville, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Cape Fear Valley Medical Center Cancer Center
mi
from
Fayetteville, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Maria Parham Medical Center
mi
from
Henderson, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Maria Parham Medical Center
mi
from
Henderson, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Southeastern Regional Medical Center
mi
from
Lumberton, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Southeastern Regional Medical Center
mi
from
Lumberton, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Granville Medical Center
mi
from
Oxford, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Granville Medical Center
mi
from
Oxford, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
mi
from
Pinehurst, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Duke Health Raleigh Hospital
mi
from
Raleigh, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Duke Health Raleigh Hospital
mi
from
Raleigh, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Person Memorial Hospital
mi
from
Roxboro, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Person Memorial Hospital
mi
from
Roxboro, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Marion L. Shepard Cancer Center at Beaufort County Hospital
mi
from
Washington, NC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Marion L. Shepard Cancer Center at Beaufort County Hospital
mi
from
Washington, NC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Keyserling Cancer Center at Beaufort Memorial Hospital
mi
from
Beaufort, SC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Keyserling Cancer Center at Beaufort Memorial Hospital
mi
from
Beaufort, SC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Coastal Cancer Center - Myrtle Beach
mi
from
Myrtle Beach, SC
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Coastal Cancer Center - Myrtle Beach
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Medical Oncology and Hematology Associates of North Virginia - Fairfax
mi
from
Fairfax, VA
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Medical Oncology and Hematology Associates of North Virginia - Fairfax
mi
from
Fairfax, VA
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
St. Mary's Regional Cancer Center at St. Mary's Medical Center
mi
from
Huntington, WV
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
St. Mary's Regional Cancer Center at St. Mary's Medical Center
mi
from
Huntington, WV
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington, D.C.,
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Washington Cancer Institute at Washington Hospital Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Walter Reed Army Medical Center
mi
from
Washington, D.C.,
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Walter Reed Army Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  8/7/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
Observational Cohort Study: Chemotherapy Decisions and Outcomes in Women Age 65 or Older With Operable, Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 8/7/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Singing River Hospital
mi
from
Pascagoula, MS
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Singing River Hospital
mi
from
Pascagoula, MS
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Medical University of South Carolina
mi
from
Charleston, SC
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Lyndon Baines Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Oklahoma Cancer Specialists and Research Institute-Tulsa
mi
from
Tulsa, OK
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
UT Southwestern/Simmons Cancer Center-Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  8/8/2017
Augusta University Medical Center
mi
from
Augusta, GA
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 8/8/2017
Augusta University Medical Center
mi
from
Augusta, GA
Click here to add this to my saved trials
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)
Status: Enrolling
Updated:  8/8/2017
University of North Dakota
mi
from
Grand Forks, ND
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors
Breast Cancer Prevention Using Synergistic Prostaglandin Inhibitors (The Vitamin D/Celecoxib Study)
Status: Enrolling
Updated: 8/8/2017
University of North Dakota
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence
Status: Enrolling
Updated:  8/8/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide
A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence
Status: Enrolling
Updated: 8/8/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
Status: Enrolling
Updated:  8/8/2017
Lester and Sue Smith Breast Center at Baylor College of Medicine
mi
from
Houston, TX
CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer
A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer
Status: Enrolling
Updated: 8/8/2017
Lester and Sue Smith Breast Center at Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  8/8/2017
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
A Phase II Trial Using Multiple Cycles of High Dose Sequential Carboplatin, Paclitaxel and Topotecan With Peripheral Blood Stem Cell (PBSC) Support as Initial Chemotherapy in Patients With Optimally Debulked Stage III Ovarian and Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 8/8/2017
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
Status: Enrolling
Updated:  8/8/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer
Status: Enrolling
Updated: 8/8/2017
Gynecologic Oncology Group of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma
Status: Enrolling
Updated:  8/15/2017
PPD Development
mi
from
Wilmington, NC
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma
Status: Enrolling
Updated: 8/15/2017
PPD Development
mi
from
Wilmington, NC
Click here to add this to my saved trials
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
Status: Enrolling
Updated:  8/16/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging
Status: Enrolling
Updated: 8/16/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2017
University of Southern California, Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/16/2017
Mayo Clinic, Department of Oncology
mi
from
Rochester, MN
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib Clinical Trial of PRI-724 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/16/2017
Mayo Clinic, Department of Oncology
mi
from
Rochester, MN
Click here to add this to my saved trials